refractory classic Hodgkin lymphoma (R/R cHL) | |
R/R cHL - second line or more (L2) | |
pembrolizumab based treatment | |
pembrolizumab alone | KEYNOTE-204 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -